10.6084/m9.figshare.8034662.v1 Chen R. Chen R. Liang B. Liang B. Wen B. Wen B. Huang G. Huang G. Ning C. Ning C. Lao C. Lao C. Jiang J. Jiang J. Liu J. Liu J. Zhou B Zhou B Huang J. Huang J. Chen J. Chen J. Zang N. Zang N. Liao Y. Liao Y. Mo D. Mo D. Ye L. Ye L. Liang H. Liang H. Supplementary Material for: No Difference in Prevalence of Transmitted Drug Resistance between Injection Drug Users and Non-Injection Drug Users: A Cross-Sectional Study among Antiretroviral Treatment-Naïve HIV Patients Karger Publishers 2019 HIV-1 Transmitted drug resistance Injection drug use 2019-04-24 10:53:55 Dataset https://karger.figshare.com/articles/dataset/Supplementary_Material_for_No_Difference_in_Prevalence_of_Transmitted_Drug_Resistance_between_Injection_Drug_Users_and_Non-Injection_Drug_Users_A_Cross-Sectional_Study_among_Antiretroviral_Treatment-Na_ve_HIV_Patients/8034662 <b><i>Objectives:</i></b> The epidemiological evidence is inconsistent about whether HIV-positive injection drug users (IDUs) are at higher risk of developing antiretroviral resistance than any other HIV-positive populations. This study aims to investigate and compare transmitted drug resistance (TDR) between IDUs and non-IDUs in Lingshan County, an HIV-hit region in Guangxi, China, where IDU and heterosexual transmission were the two dominant transmission routes and roughly equally contributed to the local HIV transmission. <b><i>Methods:</i></b> A cross-sectional study was conducted among newly diagnosed and antiretroviral-treatment (ART)-naïve HIV-1 patients from Lingshan County. The <i>pol</i> gene of HIV-1 from the individuals was sequenced followed by genotyping and TDR analysis. <b><i>Results:</i></b> Two dominant transmission routes, heterosexual contact and IDU, accounted for 49.2 and 45.9% of 183 HIV-1 infection cases, respectively. Three genotypes, including CRF08_BC (70.6%), CRF01_AE (24.4%), and CRF07_BC (5.0%), and three unique recombinant forms (1.6%), were identified. There was a significant difference in genotype distribution among the different transmission routes (<i>F</i> = 21.814, <i>p</i> < 0.001). The overall TDR prevalence was 5.5%. There were no significant differences in TDR prevalence among the different transmission routes (<i>F</i> = 1.420, <i>p</i> = 0.439). <b><i>Conclusions:</i></b> Injection drug use has little impact on TDR prevalence compared with other routes of transmission.